Literature DB >> 18392618

Progression of intracranial glioma disrupts thymic homeostasis and induces T-cell apoptosis in vivo.

Abdeljabar El Andaloussi1, Yu Han, Maciej S Lesniak.   

Abstract

The thymus is the site where all T-cell precursors develop, mature, and subsequently leave as mature T-cells. Since the mechanisms that mediate and regulate thymic apoptosis are not fully understood, we utilized a syngenic GL261 murine glioma model to further elucidate the fate of T-cells in tumor bearing C57BL/6 mice. First, we found a dramatic reduction in the size of the thymus accompanied by a decrease in thymic cellularity in response to glioma growth in the brains of affected mice. There was a marked reduction of double positive subset and an increase in the frequency of CD4(+) and CD8(+) single positive T-cell subsets. Analysis of double negative thymocytes showed an increase in the accumulation of CD44(+) cells. In contrast, there was a marked loss of CD44 and CD122 expression in CD4(+) and CD8(+) subsets. The growth of intracranial tumors was also associated with decreased levels of HO-1, a mediator of anti-apoptotic function, and increased levels of Notch-1 and its ligand, Jagged-1. To determine whether thymic atrophy could be due to the effect of Notch and its ligand expression by glioma in vivo, we performed a bone marrow transplant experiment. Our results suggest that Notch-1 and its ligand Jagged-1 can induce apoptosis of thymocytes, thereby influencing thymic development, immune system homeostasis, and function of the immune cells in a model of experimental glioma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18392618     DOI: 10.1007/s00262-008-0508-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

Review 1.  Insights into thymic involution in tumor-bearing mice.

Authors:  Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 2.  T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Pakawat Chongsathidkiet; Kristin A Keith; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

3.  A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma.

Authors:  Marie-Denise Poirier; Houda Haban; Abdeljabar El Andaloussi
Journal:  J Oncol       Date:  2010-03-21       Impact factor: 4.375

Review 4.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

5.  Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators.

Authors:  Katayoun Ayasoufi; Christian K Pfaller; Laura Evgin; Roman H Khadka; Zachariah P Tritz; Emma N Goddery; Cori E Fain; Lila T Yokanovich; Benjamin T Himes; Fang Jin; Jiaying Zheng; Matthew R Schuelke; Michael J Hansen; Wesley Tung; Ian F Parney; Larry R Pease; Richard G Vile; Aaron J Johnson
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

Review 6.  Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.

Authors:  Ana Rita Pombo Antunes; Isabelle Scheyltjens; Johnny Duerinck; Bart Neyns; Kiavash Movahedi; Jo A Van Ginderachter
Journal:  Elife       Date:  2020-02-04       Impact factor: 8.140

7.  Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.

Authors:  Erik Ladomersky; Lijie Zhai; Kristen L Lauing; April Bell; Jiahui Xu; Masha Kocherginsky; Bin Zhang; Jennifer D Wu; Joseph R Podojil; Leonidas C Platanias; Aaron Y Mochizuki; Robert M Prins; Priya Kumthekar; Jeffrey J Raizer; Karan Dixit; Rimas V Lukas; Craig Horbinski; Min Wei; Changyou Zhou; Graham Pawelec; Judith Campisi; Ursula Grohmann; George C Prendergast; David H Munn; Derek A Wainwright
Journal:  Clin Cancer Res       Date:  2020-06-16       Impact factor: 12.531

Review 8.  Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma.

Authors:  Mara De Martino; Oscar Padilla; Camille Daviaud; Cheng-Chia Wu; Robyn D Gartrell; Claire Vanpouille-Box
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

9.  U87MG glioma cells overexpressing IL-17 acclerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissues.

Authors:  Jinhui Hu; Hongxing Ye; Denghai Zhang; Weiwei Liu; Min Li; Ying Mao; Yuan Lu
Journal:  Oncol Lett       Date:  2013-08-07       Impact factor: 2.967

10.  Thymic involution, a co-morbidity factor in amyotrophic lateral sclerosis.

Authors:  Akop Seksenyan; Noga Ron-Harel; David Azoulay; Liora Cahalon; Michal Cardon; Patricia Rogeri; Minhee K Ko; Miguel Weil; Shlomo Bulvik; Gideon Rechavi; Ninette Amariglio; Eli Konen; Maya Koronyo-Hamaoui; Raz Somech; Michal Schwartz
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.